N6-methylation in the development, diagnosis, and treatment of gastric cancer

Jiaxin Wang; Guiping Zhao; Yan Zhao; Zheng Zhao; Shuyue Yang; Anni Zhou; Peng Li; Shutian Zhang

doi:10.2478/jtim-2023-0103

N⁶-methylation in the development, diagnosis, and treatment of gastric cancer

J Transl Int Med. 2024 Mar 21;12(1):5-21. doi: 10.2478/jtim-2023-0103. eCollection 2024 Feb.

Authors

Jiaxin Wang¹, Guiping Zhao¹, Yan Zhao¹, Zheng Zhao¹, Shuyue Yang¹, Anni Zhou¹, Peng Li¹, Shutian Zhang¹

Affiliation

¹ Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.

Abstract

Gastric cancer (GC) ranks third among cancers in terms of mortality rate worldwide. A clear understanding of the mechanisms underlying the genesis and progression of GC will contribute to clinical decision making. N⁶-methyladenosine (m⁶A) is the most abundant among diverse mRNA modification types and regulates multiple facets of RNA metabolism. In recent years, emerging studies have shown that m⁶A modifications are involved in gastric carcinoma tumorigenesis and progression and can potentially be valuable new prospects for diagnosis and prognosis. This article reviews the recent progress regarding m⁶A in GC.

Keywords: N6-methyladenosine; gastric cancer; metastasis; tumorigenesis.

Grants and funding

Preparation of the present review article was supported by the National Natural Science Foundation of China (grant no. 82070575), the Capital’s Funds for Health Improvement and Research (grant no. 2020-2-2026), the Beijing Hospitals Authority Clinical Technology Innovation Project (grant no. XMLX202131), Beijing Hospitals Authority “Dengfeng” talent training plan (grant no. DFL20220101), and the Natural Cultivation Foundation of Capital Medical University (grant no. PYZ21049).